Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aerovate Therapeutics Inc (NQ: AVTE )

2.620 -0.040 (-1.50%)
Streaming Delayed Price Updated: 2:35 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 75,066
Open 2.650
Bid (Size) 2.610 (102)
Ask (Size) 2.620 (7)
Prev. Close 2.660
Today's Range 2.570 - 2.680
52wk Range 1.250 - 32.41
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Air Transport Services Group, Inc. (Nasdaq– ATSG), Micropac Industries, Inc. (OTC - MPAD), Aerovate Therapeutics, Inc. (Nasdaq - AVTE), Outbrain Inc. (Nasdaq - OB)
From Brodsky & Smith LLC
Via GlobeNewswire

Performance

YTD
-87.99%
-87.99%
1 Month
+11.97%
+11.97%
3 Month
+39.36%
+39.36%
6 Month
-85.44%
-85.44%
1 Year
-81.93%
-81.93%

More News

Read More
“The Future is Bright: Peraso Inc. (NASDAQ: PRSO) Expands Technology for Tactical Applications in High-Demand Industries – More Stocks Inside…”
Via AB Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi LLP
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
From Jade Biosciences
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Aerovate Therapeutics to Explore Strategic Alternatives
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
The 3 Hottest Stock Downgrades From Last Week
Via InvestorPlace
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
Via Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke
Via Investor's Business Daily
Why Is Small Cap-Heart Disease Focused Aerovate Therapeutics Stock Plummeting On Monday?
Via Benzinga
US Stocks Mixed; Dow Tumbles Over 100 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.